Others have shown that TP53 mutations are necessary for the malignant progression of breast cancer from lower to higher grades [38] and that these mutations therefore significantly correlate to a higher mitotic count and a higher risk group in GIST [34]. The gene discussed is TP53; the disease is breast carcinoma.